RET fusion-positive NSCLC patients show poorer tumor cell differentiation, more signet ring cell subtypes, and smaller primary lesions (<3 cm) when compared to ALK rearrangement, EGFR receptor mutation, and ROS-1 fusion-positive patients (22, 51, 53). This evidence concerns the gene ALK and non-small cell lung carcinoma.